Novartis plans to cut 130 jobs in Switzerland by phasing out biologics production at Kleinbasel by 2027 and relocating labs to its main Basel campus by 2028. The restructuring aims to consolidate operations, with a social plan provided for affected workers. 'These planned changes support our long-term strategy', said Steffen Lang, President of Operations. Novartis Layoffs: Drugmaker To Cut 130 Jobs in Switzerland Amid Biologics Rework.